Microbot Medical Files S-1 for Public Offering

TL;DR

Microbot Medical is filing an S-1, likely raising cash for growth.

AI Summary

Microbot Medical Inc. filed an S-1 form on June 11, 2024, indicating a public offering of securities. The company, previously known as Cytotherapeutics Inc./DE and StemCells Inc., is based in Hingham, MA, and operates in the surgical and medical instruments sector. This filing suggests the company is seeking to raise capital through the sale of its stock.

Why It Matters

This S-1 filing signals Microbot Medical Inc.'s intention to raise capital, which could fund further development of its medical technologies or expansion of its business operations.

Risk Assessment

Risk Level: medium — S-1 filings often indicate a company is seeking to raise capital, which can be a positive sign for growth but also carries inherent risks associated with public offerings and the company's specific financial situation.

Key Numbers

• 20240611 — Filing Date (Indicates when the S-1 was submitted to the SEC.)
• 333-280113 — SEC File Number (Unique identifier for the registration statement.)

Key Players & Entities

• Microbot Medical Inc. (company) — Filer of the S-1 form
• June 11, 2024 (date) — Date of filing
• S-1 (document) — Type of SEC filing
• Cytotherapeutics Inc./DE (company) — Former company name
• StemCells Inc. (company) — Former company name
• Hingham, MA (location) — Company business address
• 3841 (industry_code) — Standard Industrial Classification for Surgical & Medical Instruments & Apparatus

FAQ

Key Financial Figures

• $0.01 — o 3,211,671 shares of our common stock, $0.01 par value per share, representing share
• $1.08 — stock on the Nasdaq Capital Market was $1.08. Investing in our common stock involv
• $1.50 — ur common stock at an offering price of $1.50 per share. In a concurrent private plac
• $2.35 million — ne 4, 2024, and we raised approximately $2.35 million in aggregate gross proceeds from such o
• $1.875 — issuance, and have an exercise price of $1.875 per share. FDA Approval to Proceed wi
• $6.75 million — f the SPA and return of the Plaintiffs' $6.75 million purchase price with respect to the Fina
• $2,154,000 — Company paid Plaintiffs an aggregate of $2,154,000 (the "Total Settlement Amount"), consis
• $1,100,000 — d by the Company's insurance carrier of $1,100,000 and 1,005,965 shares of restricted Comp
• $1,054,000 — ated pursuant to the following formula: $1,054,000/[closing price of Company common stock
• $2.20 — 's common stock at an exercise price of $2.20 per share, issued on October 25, 2022,
• $2.075 — 's common stock at an exercise price of $2.075 per share, issued on June 6, 2023, and
• $3.19 — 's common stock at an exercise price of $3.19 per share issued on June 26, 2023 (the
• $1.62 — stock, at a reduced exercised price of $1.62 per share, in consideration for the Com

Filing Documents

• forms-1.htm (S-1) — 2338KB
• ex5-1.htm (EX-5.1) — 14KB
• ex23-1.htm (EX-23.1) — 4KB
• ex107.htm (EX-FILING FEES) — 22KB
• forms-1_001.jpg (GRAPHIC) — 6KB
• fin_001.jpg (GRAPHIC) — 4KB
• fin_002.jpg (GRAPHIC) — 23KB
• ex5-1_001.jpg (GRAPHIC) — 51KB
• 0001493152-24-023434.txt ( ) — 8834KB
• mbot-20240331.xsd (EX-101.SCH) — 66KB
• mbot-20240331_cal.xml (EX-101.CAL) — 66KB
• mbot-20240331_def.xml (EX-101.DEF) — 252KB
• mbot-20240331_lab.xml (EX-101.LAB) — 405KB
• mbot-20240331_pre.xml (EX-101.PRE) — 332KB
• forms-1_htm.xml (XML) — 1360KB

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 37

BUSINESS

BUSINESS 38 BOARD OF DIRECTORS AND MANAGEMENT 52 EXECUTIVE COMPENSATION 57 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 62 SECURITY 63

DILUTION

DILUTION 64 SELLING STOCKHOLDERS 64 PLAN OF DISTRIBUTION 65 DESCRIPTION OF CAPITAL STOCK 6 6 LEGAL MATTERS 69 EXPERTS 69 WHERE YOU CAN FIND MORE INFORMATION 69 FINANCIAL F-1 ABOUT THIS PROSPECTUS You should rely only on the information that we have provided in this prospectus and any prospectus supplement that we may authorize to be provided to you. We have not, and the selling stockholders have not, authorized anyone to provide you with different information. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus or any prospectus supplement that we may authorize to be provided to you. If anyone provides you with different or inconsistent information, you should not rely on it. You should assume that the information in this prospectus and any prospectus supplement is accurate only as of the date on the cover of the document, regardless of the time of delivery of this prospectus or any prospectus supplement or any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates. We urge you to carefully read this prospectus and any prospectus supplement, together with the information as described under the heading "Where You Can Find More Information." Unless the context indicates otherwise, as used in this prospectus, the terms "we," "us," "our," the "Company" and "Microbot" refer to Microbot Medical Inc., including our directly and indirectly wholly owned subsidiary. Unless the context otherwise requires, the historical business, financial statements and operations of Microbot include Microbot Medical Ltd., an Israeli corporation ("Microbot Israel") which became a wholly-owned subsidiary of the Company on November 28, 2016. We own or have rights to various U.S. federal trademark registrations and applications, and unregistered trademarks and servicemarks, including LIBERTY . All othe

View Full Filing

View this S-1 filing on SEC EDGAR